Compare DexCom, Inc. (DXCM) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Marriott International Inc — how do they compare? DexCom, Inc. trades at $84.03 (market cap $31.86B), while Marriott International Inc trades at $365.05 (market cap $94.16B). The key difference: Marriott International Inc is far larger — about 3× DexCom, Inc.'s market cap, and Marriott International Inc pays a 0.81% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Marriott International Inc for 164 Days on average.
| DXCM | MAR | |
|---|---|---|
Market Cap | $31.86B | $94.16B |
Volume | 3,607,070 | 996,176 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $402.54 |
52-Week Low | $54.84 | $259.04 |
Typical Hold Time | 62 Days | 164 Days |
Enterprise Value | $31.32B | $111.47B |
Dividend Yield | — | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Marriott International (MAR) trades at $363.49, up 1.96% today, showing strong momentum near resistance at $364. The stock maintains a bullish technical outlook with positive moving averages and ADX signals. Fundamentally, revenue grew to $26.19B in 2025 with a 9.62% net margin, though valuation metrics appear elevated with a P/E of 37.38. Recent earnings beat expectations in Q1 and Q2 2026, while analysts maintain a consensus price target of $386.71 with 44% buy ratings.
Outlook remains positive driven by travel demand recovery and strategic partnerships, but risks include rising debt levels (debt-to-asset ratio at 58.83% in 2025) and economic sensitivity. The stock offers moderate upside to analyst targets with institutional confidence, though high valuation requires sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
